These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14735701)

  • 1. Doxorubicin for metastatic breast cancer: time for a change?
    Muggia F
    Cancer Invest; 2003; 21(6):967-8. PubMed ID: 14735701
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
    Bernardi D; Errante D; Stefani M; Salvagno L
    Breast; 2010 Dec; 19(6):549-50. PubMed ID: 20542696
    [No Abstract]   [Full Text] [Related]  

  • 3. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
    Gabizon AA
    Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.
    Minisini AM; Andreetta C; Fasola G; Puglisi F
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):331-42. PubMed ID: 18366282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
    Anand A; Anand A
    J Natl Cancer Inst; 1995 Nov; 87(21):1642. PubMed ID: 7563210
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
    Paridaens R
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
    Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
    Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.
    Murphy CG; Khasraw M; Seidman AD
    Breast Cancer Res Treat; 2010 Jul; 122(1):177-9. PubMed ID: 20458530
    [No Abstract]   [Full Text] [Related]  

  • 10. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.
    Perez AT; Domenech GH; Frankel C; Vogel CL
    Cancer Invest; 2002; 20 Suppl 2():22-9. PubMed ID: 12442346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?
    Fabi A; Ferretti G; Salesi N; Papaldo P; Carlini P; Ciccarese M; Di Cocco B; Cecere F; Nardoni C; Felici A; Cognetti F
    Ann Oncol; 2005 Mar; 16(3):516-7. PubMed ID: 15642705
    [No Abstract]   [Full Text] [Related]  

  • 12. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
    J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience.
    Gianni L
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):13-5. PubMed ID: 9516596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?
    Grenader T; Gabizon A
    J Clin Oncol; 2010 Apr; 28(12):e193-4; author reply e195-6. PubMed ID: 20194839
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?
    Bielack SS; Erttmann R; Kempf-Bielack B; Winkler K
    Eur J Cancer; 1996 Sep; 32A(10):1652-60. PubMed ID: 8983270
    [No Abstract]   [Full Text] [Related]  

  • 17. A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer.
    Chao TC; Wang WS; Yen CC; Chiou TJ; Liu JH; Chen PM
    Cancer Invest; 2003; 21(6):837-47. PubMed ID: 14735687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
    Valero V; Perez E; Dieras V
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):15-23. PubMed ID: 11552226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer.
    Martino S; Samal BA; Redman B; Flaherty L; Kraut M; Simon M; Valdivieso M
    Breast Cancer Res Treat; 1990 Dec; 17(2):139-43. PubMed ID: 2096991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.